Regulatory T cells and Autoimmune Diseases

1st Edition - May 24, 2024
Editors: Mitesh Kumar Dwivedi, DeLisa Fairweather
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 9 4 7 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 3 9 4 8 - 2

Regulatory T Cells and Autoimmune Diseases addresses recent findings concerning the role of Tregs in the pathogenesis of autoimmune diseases as well as their therapeutic applicati… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Regulatory T Cells and Autoimmune Diseases addresses recent findings concerning the role of Tregs in the pathogenesis of autoimmune diseases as well as their therapeutic applications. In particular, this book deals with various Treg-based mechanisms that can lead to autoimmune disease and covers different aspects linking Tregs with autoimmune mechanisms involved in disease development by discussing animal models and human studies.

This book specifically focuses on Treg-based therapeutics and their targets to manage all known autoimmune rheumatic, central nervous system, bowel, liver, thyroid, kidney, myopathic, skin, blood and blood vessel, and eye diseases and aims to provide a must-have reference for designing therapeutic strategies to treat these autoimmune diseases. Additionally, this book covers vaccine-induced effects on the functioning of Tregs and development of CAR Treg therapy for autoimmune diseases and concludes with current challenges and future prospects of Treg-based therapeutics. This book is carefully designed to meet the requirements of both basic and advanced researchers in the area and provide new dimensions and insight into regulatory T cells’ role in autoimmune disease pathogenesis and therapy.

Part I Regulatory T cells and immune system

1. Regulatory T cells and their functions in immune system

2. Regulatory T cells: mechanisms of action

3. Regulatory T cells and autoimmunity

4. Sex differences in regulatory T cells during autoimmune disease

Part II Role of regulatory T cells in central nervous system demyelinating autoimmune diseases

5. Role of regulatory T cells in pathogenesis and therapeutics of systemic lupus erythematosus

6. Role of regulatory T cells in the pathogenesis and therapeutics of primary Sjögren’s syndrome

7. Role of regulatory T cells in pathogenesis and therapeutics of rheumatoid arthritis and juvenile idiopathic arthritis

8. Role of regulatory T cells in pathogenesis and therapeutics of psoriatic arthritis

9. Role of regulatory T cells in pathogenesis and therapeutics of spondyloarthritis

10. Role of regulatory T cells in pathogenesis and therapeutics of ankylosing spondylitis

Part III Role of regulatory T cells in central nervous system demyelinating autoimmune diseases

11. Role of regulatory T cells in pathogenesis and therapeutics of multiple sclerosis

12. Role of regulatory T cells in the pathogenesis and therapeutics of neuromyelitis optica spectrum disorder

Part IV Role of regulatory T cells in peripheral nerve, muscle and neuromuscular autoimmune diseases

13. Role of regulatory T cells in pathogenesis and therapeutics of myasthenia gravis

14. Role of regulatory T cells in pathogenesis and therapeutics of GuillainBarré syndrome and experimental autoimmune neuritis

15. Role of regulatory T cells in pathogenesis and therapeutics of chronic inflammatory demyelinating polyradiculoneuropathy

16. Role of regulatory T cells in pathogenesis and therapeutics of dermatomyositis and polymyositis

Part V Role of regulatory T cells in inflammatory bowel diseases

17. Role of regulatory T cells in pathogenesis and therapeutics of Crohn’s disease and ulcerative colitis

18. Role of regulatory T cells in pathogenesis and therapeutics of celiac disease

Part VI Role of regulatory T cells in autoimmune liver diseases

19. Role of regulatory T cells in the pathogenesis and therapeutics of autoimmune hepatitis

20. Role of regulatory T cells in pathogenesis and therapeutics of primary biliary cholangitis and primary sclerosing cholangitis

Part VII Role of regulatory T cells in autoimmune thyroid diseases

21. Role of regulatory T cells in pathogenesis and therapeutics of Hashimoto’s thyroiditis

22. Role of regulatory T cells in pathogenesis and therapeutics of Graves’ disease and Graves’ orbitopathy

Part VIII Role of regulatory T cells in autoimmune lung and kidney diseases

23. Role of regulatory T cells in pathogenesis and therapeutics of Goodpasture’s syndrome (anti-glomerular basement membrane disease)

24. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune glomerulonephritis (IgA vasculitis and IgA nephropathy)

Part IX Role of regulatory T cells in autoimmune skin diseases

25. Role of regulatory T cells in pathogenesis and therapeutics of vitiligo

26. Role of regulatory T cells in pathogenesis and therapeutics of psoriasis

27. Role of regulatory T cells in pathogenesis and therapeutics of atopic dermatitis

28. Role of regulatory T cells in pathogenesis and therapeutics of alopecia areata

29. Role of regulatory T cells in pathogenesis and therapeutics of pemphigus vulgaris and bullous pemphigoid

30. Role of regulatory T cells in pathogenesis and therapeutics of scleroderma (systemic sclerosis)

Part X Role of regulatory T cells in autoimmune blood and blood vessel disorders

31. Role of regulatory T cells in pathogenesis and therapeutics of primary antiphospholipid syndrome (Hughes syndrome)

32. Role of regulatory T cells in pathogenesis and therapeutics of Kawasaki disease

33. Role of regulatory T cells in pathogenesis and therapeutics of Behçet disease

34. Role of regulatory T cells in pathogenesis and therapeutics of immune thrombocytopenia

35. Role of regulatory T cells in pathogenesis and treatment of antineutrophil cytoplasmic antibody-associated vasculitis

36. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune hemolytic anemia

Part XI Role of regulatory T cells in autoimmune eye diseases and type 1 diabetes mellitus

37. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune uveitis

38. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune retinopathy

39. Role of regulatory T cell in pathogenesis and therapeutics of type 1 diabetes mellitus

Part XII Current challenges and future prospects in research towards regulatory T cells based therapeutics in autoimmune diseases

40. Vaccines induced effects on functioning of regulatory T cells: autoimmune perspective

41. Probiotic interventions for regulatory T cells’ induction in autoimmune diseases

42. CAR Treg-based therapeutics for autoimmune diseases

43. Current challenges and future prospects of regulatory T cells based therapeutics in autoimmune disease

Mitesh Kumar Dwivedi

Mitesh Kumar Dwivedi, PhD, is an assistant professor of microbiology at the C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University. He has published 63 research papers and 46 book chapters, edited 8 books, and serves as an editorial board member and reviewer of many international journals. He has an h-index of 25 with 2261 citations for his research papers. His research interests include investigation of immunogenetic, autoimmune, and therapeutic aspects of vitiligo, rheumatoid arthritis, sickle cell disease, and the role of probiotics in amelioration of autoimmune diseases. He is a recipient of numerous honors: DST-SERB Core Research Grant (2022), SERB-SIRE International Research Fellowship (2022), Best Researcher Award (2020), INSA Visiting Scientist Award (2019), DST-SERB Early Career Research Award (2018), Young Scientist Awards (2011, 2013, and 2018), and all India rank “32” in CSIR-NET national examination (2011; Life Sciences). He has successfully completed six research projects as principal investigator from national funding agencies: SERB-DST, GUJCOST, UTU, and Neo Sciences & Research Solutions Pvt. Ltd. and guided students for their doctoral and master degrees.

Affiliations and expertise

Assistant Professor of Microbiology, C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University, India

DeLisa Fairweather

DeLisa Fairweather, PhD, is a professor of medicine and immunology and director of translational research in the Department of Cardiovascular Medicine at Mayo Clinic in Jacksonville, Florida, studying sex/gender differences in cardiovascular and autoimmune diseases, including myocarditis. Her research has been continuously funded by the National Institutes of Health (NIH), the American Heart Association (AHA), BARDA, and others. She serves on NIH, the Board of the Atwal Clinic and Mayo Clinic Mitochondrial Research Center, and formerly on the Board of the Myocarditis Foundation. She was a leader of the US FDA Mayo-led Expanded Access Program during the COVID-19 pandemic. She has served on the National Academies of Sciences, Engineering, and Medicine (NASEM) committee making recommendations to NIH and Congress on the autoimmune disease portfolio of NIH and on the NASEM committee to examine side effects of COVID-19 vaccines. She is a member of the Scientific Advisory Board for the Autoimmune Registry as well as the Organization for the Study of Sex Differences (OSSD).

Affiliations and expertise

Director of Translational Research Department Cardiovascular Medicine, Mayo Clinic, USA